Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1738]

What does progression-free survival mean for breast cancer patients?

Dr Peter Schmid - Barts Cancer Institute, London, UK

What does progression-free survival mean for breast cancer patients? ( Dr Peter Schmid - Barts Cancer Institute, London, UK )

ASCO 2018: Novel treatment strategies in prostate cancer therapeutics

Prof Karim Fizazi and Dr Neal Shore

ASCO 2018: Novel treatment strategies in prostate cancer therapeutics ( Prof Karim Fizazi and Dr Neal Shore )

ASCO 2018: Latest developments in non-metastatic and metastatic castration...

Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik

ASCO 2018: Latest developments in non-metastatic and metastatic castration-resistant prostate cancer ( Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik )

Education, collaboration and communication in global cancer control

Dr Susannah Stanway - Royal Marsden NHS Foundation Trust, London, UK

Education, collaboration and communication in global cancer control ( Dr Susannah Stanway - Royal Marsden NHS Foundation Trust, London, UK )

Treatment updates in Merkel cell carcinoma

Dr Paul Nghiem - University of Washington, Seattle, USA

Treatment updates in Merkel cell carcinoma ( Dr Paul Nghiem - University of Washington, Seattle, USA )

ASCO 2018: Latest in bladder cancer treatments

Prof Thomas Powles & Prof Shahrokh Shariat

ASCO 2018: Latest in bladder cancer treatments ( Prof Thomas Powles & Prof Shahrokh Shariat )

ASCO 2018: Integrating genomic data throughout treatment for prostate cancer

Prof Kurt Miller and Prof Bertrand Tombal

ASCO 2018: Integrating genomic data throughout treatment for prostate cancer ( Prof Kurt Miller and Prof Bertrand Tombal )

Zoptarelin no better than doxarubicin for second-line advanced endometrial...

Dr David Miller - The University of Texas Southwestern Medical Center

Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer ( Dr David Miller - The University of Texas Southwestern Medical Center )

Immunotherapy trials and hyperprogressive disease

Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain

Immunotherapy trials and hyperprogressive disease ( Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

First-in-human phase 1 study of TAK-931 for solid tumours

Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan

First-in-human phase 1 study of TAK-931 for solid tumours ( Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan )

Web-mediated follow-up via patient-reported outcomes vs. routine surveillance...

Dr Fabrice Denis - Jean Bernard Centre, Le Mans, France

Web-mediated follow-up via patient-reported outcomes vs. routine surveillance in lung cancer patients ( Dr Fabrice Denis - Jean Bernard Centre, Le Mans, France )

The CAPTIVATE trial of ibrutinib and venetoclax as a first line treatment for...

Prof William Wierda - MD Anderson Cancer Center, Houston, USA

The CAPTIVATE trial of ibrutinib and venetoclax as a first line treatment for CLL patients ( Prof William Wierda - MD Anderson Cancer Center, Houston, USA )

More from ecancer